کتامین؛ استفاده و سوء استفاده: آسیب‌های ناشی از مصرف خودسرانه‌ی آن، یک مطالعه مروری

نوع مقاله : مروری

نویسندگان

1 دانشیار، عضو هیات علمی بخش جراحی و رادیولوژی، دانشکده دامپزشکی، دانشگاه شهرکرد، ایران

2 دانش‌آموخته دکترای عمومی دامپزشکی

3 دانشجوی دکترای عمومی دامپزشکی، دانشگاه شهرکرد، ایران

چکیده

چکیده
زمینه و هدف: کتامین یک ماده بی‌هوش‌ کننده انفکاکی بوده که به دلیل مزیت‌های خود یعنی خواص بی‌هوشی با کمترین تاثیر روی دستگاه تنفسی و قلبی-عروقی به فراوانی در پزشکی و دامپزشکی مورد استفاده قرار می‌گیرد. اما در سال‌های اخیر به جهت سوء استفاده از آن، به عنوان یک داروی مشکل‌ساز مطرح شده و استفاده آن در بسیاری از نقاط جهان افزایش‌ یافته است و طبق گزارش جهانی دفتر مواد مخدر و جرم سازمان ملل، استفاده از این دارو در سراسر شرق آسیا، استرالیا، شمال امریکا و اروپا رو به گسترش است و در بخش‌هایی از جنوب شرق آسیا استفاده از کتامین به دلیل عدم وجود محدودیت‌های بین‌المللی در مواد مخدر و در دسترس بودن آن، به طرز چشم‌گیری افزایش‌ یافته است. تحقیقات اخیر نشان داده سوء استفاده از کتامین و مصرف طولانی مدت آن باعث بروز تغییر در حالات رفتاری شده، همچنین باعث عوارض فیزیکی متعددی مانند آسیب‌ در دستگاه‌ ادراری، بافت عصبی و نارسایی‌های کبدی در بین مصرف‌کنندگان می‌گردد.
مواد و روش‌ها: این مطالعه مروری با استفاده از کلمات کلیدی کتامین، بی‌هوشی و سوء استفاده نگارش شده است. مقالات مربوط به سال‌های 1978 تا 2016 انتخاب شدند.
نتایج: در این پژوهش ابتدا داروی کتامین معرفی و سپس موارد استفاده و سوء استفاده، آسیب‌های ناشی از مصرف خودسرانه و قوانین مربوط به تجویز آن در برخی کشورها بحث و در نهایت روش‌های شناسایی و اندازه‌گیری آن بیان شده است.

کلیدواژه‌ها

موضوعات


عنوان مقاله [English]

Ketamine; Use, Abuse: Damages caused by its arbitrary use; A review article

نویسندگان [English]

  • Moosa Javdani 1
  • Rasoul Rahimi 2
  • Abolfazl Barzegar Bafrouei 3
1 Associate Professor, DVM, DVSc in Veterinary Surgery & Radiology, Department of Veterinary Clinical Sciences, Shahrekord University, Iran
2 DVM Graduated in Veterinary Medicine
3 Veterinary Faculty- Shahrekord University
چکیده [English]

Abstract
Background: Ketamine is a dissociative anesthetic that because of its minimal effects on respiratory and cardiovascular systems, frequently used in both human and veterinary medicine. But in recent years, it was recognized as a problematic drug of abuse and became increasing popular in many parts of the world. According to the United Nations Office on Drugs and Crime report, use of ketamine in East Asia, Australia, North America and Europe was increasing, also in parts of South East Asia because of less International Drug Control and availability of ketamine use of its dramatically increased. Recent studies showed that abuse and long-term use of ketamine cause changes in mood, and physical condition such as damage in the urinary tract, nervous tissue and liver failure among consumers.
Materials and Methods: The review article is written by the keywords “ketamine, anesthesia, abuse”. articles that published in 1978- 2016 were selected.
Results: In this study, ketamine introduced initially; then use, abuse, damage caused by arbitrary use and legality of ketamine in some countries discussed and finally methods for the determination of ketamine were mentioned.

کلیدواژه‌ها [English]

  • ketamine
  • anesthesia
  • abuse
1]. Morgan, C. J., Muetzelfeldt, L., & Curran, H. V . Consequences of chronic ketamine self‐administration upon neurocognitive function and psychological wellbeing: a 1‐year longitudinal study. Addiction. 2010; 105(1), 121-133.
[2]. Declared, D. M. Findings from the 2008/09 British Crime Survey. England and Wales. Home Office Statistical Bulletin. 2009.
[3]. McCambridge, J., Winstock, A., Hunt, N., & Mitcheson, L. 5-Year trends in use of hallucinogens and other adjunct drugs among UK dance drug users. European addiction research. 2006; 13(1), 57-64.
[4]. Johnston, L. Monitoring the future: National results on adolescent drug use: Overview of key findings: DIANE Publishing. 2010.
[5]. Dalgarno, P J., & Shewan, D. Illicit use of ketamine in Scotland. Journal of psychoactive drugs. 1996; 28(2), 191-199.
[6]. Redig, P., Larson, A., & Duke, G. Response of great horned owls given the optical isomers of ketamine. American journal of veterinary research. 1984; 45(1), 125-127.
[7]. Muir 3rd, W., & Hubbell, J. Cardiopulmonary and anesthetic effects of ketamine and its enantiomers in dogs. American journal of veterinary research. 1988; 49(4), 530-534. 
[8]. Orser, B. A., Pennefather, P. S., & MacDonald, J. F. Multiple mechanisms of ketamine blockade of N-methyl-D-aspartate receptors. The Journal of the American Society of Anesthesiologists. 1997; 86(4), 903-917.
[9]. Stotz, M., Oehen, H.-P., & Gerber, H. Histological findings after long-term infusion of intrathecal ketamine for chronic pain: a case report. Journal of pain and symptom management. 1999; 18(3), 223-228.
[10]. Mody, I., & MacDonald, J. F. NMDA receptor-dependent excitotoxicity: the role of intracellular Ca 2+ release. Trends in pharmacological sciences. 1995; 16(10), 356-359.
[11]. Legrand, T., Roy, S., Monchaud, C., Grondin, C., Duval, M., & Jacqz-Aigrain, E. Determination of ketamine and norketamine in plasma by micro-liquid chromatography–mass spectrometry. Journal of pharmaceutical and biomedical analysis. 2008; 48(1),171-176.
[12]. Huang, M.-K., Liu, C., Li, J.-H., & Huang, S.-D. Quantitative detection of ketamine, norketamine, and dehydronorketamine in urine using chemical derivatization followed by gas chromatography–mass spectrometry. Journal of Chromatography B. 2005; 820(2), 165-173.
 [13]. Chen, C.-Y., Lee, M.-R., Cheng, F.-C., & Wu, G.-J. Determination of ketamine and metabolites in urine by liquid chromatography–mass spectrometry. Talanta. 2007; 72(3), 1217-1222.
[14]. Aboul-Enein, H. Y., & Hefnawy, M. M. Liquid chromatographic high-throughput analysis of ketamine and its metabolites in human plasma using a monolithic silica column and solid phase extraction. Talanta. 2005; 65(1), 67-73.
[15]. Cheng, P.-S., Lee, C.-H., Liu, C., & Chien, C.-S. Simultaneous determination of ketamine, tramadol, methadone, and their metabolites in urine by gas chromatography-mass spectrometry. Journal of analytical toxicology. 2008; 32(3), 253-259.
[16]. Lynch, M. E., Clark, A. J., Sawynok, J., & Sullivan, M. J. Topical amitriptyline and ketamine in neuropathic pain syndromes: an open-label study. The Journal of Pain. 2005; 6(10), 644-649.
[17].  Javdani M, Nikousefat Z, Ghashghaei A, Hashemnia M. Efficacy of Ketamine in Combination with Four Common Analgesics on Some Hematological Factors of Broiler Chickens International Journal of Livestock Research. 2014; 2:33-41.
[18]. Javdani M, Nikousefat Z  "Evaluation of  pain relieving of low dose of ketamine and tramadol accompanied by local anesthesia in cats undergoing bone marrow aspiration " 3rd International Congress of Veterinary Pharmacology and Pharmaceutical Sciences. 2016.
[19]. Javdani M, Khosravi M, Raeisi M, Rahimi R, Hashemi A  "Evaluation of canine behavior following repeated, long-term administration of low-dose ketamine  " 3rd international congress of veterinary pharmacology & pharmaceutical sciences. 2016.
[20]. Javdani M, Tamadon  A, Attaran H. Comparison of different Ketamine-xylazine combinations for prolonged anaesthesia in budgerigars (Melopsittacus Undulatus) Vet Scan 4. 2009.
[21]. Correll, G. E., Maleki, J., Gracely, E. J., Muir, J. J., & Harbut, R. E. Subanesthetic ketamine infusion therapy: a retrospective analysis of a novel therapeutic approach to complex regional pain syndrome. Pain Medicine. 2004; 5(3), 263-275.
[22]. Fujikawa, D. G. Neuroprotective effect of ketamine administered after status epilepticus onset. Epilepsia. 1995; 36(2), 186-195.
[23]. Larkin, G. L., & Beautrais, A. L. A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. International Journal of Neuropsychopharmacology. 2011; 14(8), 112.1131-7.
[24]. Thakurta, R. G., Das, R., Bhattacharya, A. K., Saha, D., Sen, S., Singh, O. P., & Bisui, B. Rapid response with ketamine on suicidal cognition in resistant depression. Indian journal of psychological medicine. 2012; 34(2), 170.
[25]. Kashani, P., Yousefian, S., Amini, A., Heidari, K., Younesian, S., & Hatamabadi, H. R. The effect of intravenous ketamine in suicidal ideation of emergency department patients. Emergency. 2014; 2(1), 36.
[26]. Krupitsky, E., & Grinenko, A. Ketamine psychedelic therapy (KPT): a review of the results of ten years of research. Journal of psychoactive drugs. 1997; 29(2), 165-183.
[27]. Krystal, J. H. Ketamine and the potential role for rapid-acting antidepressant medications. Swiss medical weekly. 2007; 137(15/16), 215.
[28]. Administration, S.A.M.H.S. The NSDUH Report Use of Specific. 2008.
 
[29]. Breen, C., Degenhardt, L., White, B., Bruno, R., Chanteloup, F., Fisher, J., Johnston, J., Kinner, S., Moon, C., Proufoot, P., et al. Australian party drugs trends 2003: Findings from the party drug initiative. . Sydney: National Drug and Alcohol Research Centre.2008.
 
[30].Tang, M., Ching, C.K., Tse, M.L., Ng, C., Lee, C., Chong, Y.K., Wong, W., Mak, T.W., Emerging Drugs of Abuse Surveillance Study, G. Surveillance of emerging drugs of abuse in Hong Kong: validation of an analytical tool. Hong Kong Med J. 2015; 21, 114-123.
[31]. Tang, J., Liao, Y., He, H., Deng, Q., Zhang, G., Qi, C., Cui, H., Jiao, B., Yang, M., Feng, Z., et al. Sleeping problems in Chinese illicit drug dependent subjects. BMC Psychiatry.2015; 15, 28.
[32]. Katzung, B. G., Susan, B., & Trevor, A. Lange Basic and Clinical Pharmacology: San Francisco, CA: McGraw Hill Medical. 2007.
[33]. Keilhoff, G., Bernstein, H.-G., Becker, A., Grecksch, G., & Wolf, G. Increased neurogenesis in a rat ketamine model of schizophrenia. Biological psychiatry. 2004; 56(5), 317-322.
[34]. Becker, A., Peters, B., Schroeder, H., Mann, T., Huether, G., & Grecksch, G. Ketamine-induced changes in rat behaviour: a possible animal model of schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2003; 27(4), 687-700.
[35]. Lilly, J. C. The scientist: A novel autobiography: Lippincott Williams & Wilkins.1978.
[36]. Jansen, K. Ketamine: dreams and realities. Multidisciplinary association for psychedelic studies. MAPS, Sarasota, FL. 2001.
[37]. Bergman, J., Paronis, C.A. Measuring the reinforcing strength of abused drugs. Mol Interv.2006; 6, 273-283.
 
[38]. Chen, W.Y., Huang, M.C., Lin, S.K. Gender differences in subjective discontinuation symptoms associated with ketamine use. Subst Abuse Treat Prev Policy.2014; 9, 39.
[39]. Cami, J., Farre, M. Drug addiction. N Engl J Med.2003; 349, 975-986.
[40]. Tedesco, V., Ravagnani, C., Bertoglio, D., Chiamulera, C. Acute ketamine-induced neuroplasticity: ribosomal protein S6 phosphorylation expression in drug addiction-related rat brain areas. Neuroreport.2013; 24, 388-393.
[41]. Morgan, C.J.A., Muetzelfeldt, L., Curran, H.V. Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study. Addiction.2010; 105, 121–133.
[42]. Littlewood, C.L., Jones, N., O’Neill, M.J., Mitchell, S.N., Tricklebank, M., Williams, S.C.R. Mapping the central effects of ketamine in the rat using pharmacological MRI. Psychopharmacology.2006; 186, 64-81.
[43]. Muetzelfeldt, L., Kamboj, S., Rees, H., Taylor, J., Morgan, C., & Curran, H. Journey through the K-hole: phenomenological aspects of ketamine use. Drug and alcohol dependence. 2008; 95(3), 219-229. 
 [44]. Ivani, G., Vercellino, C., & Tonetti, F. Ketamine: a new look to an old drug. Minerva anestesiologica. 2003; 69(5), 468-471.
[45]. Grant, I., Nimmo, W., & Clements, J. Pharmacokinetics and analgesic effects of im and oral ketamine. British Journal of Anaesthesia. 1981; 53(8), 805-810.
[46]. Wong, S., Lee, K., Wong, J., Ng, W., Cheung, Y., & Lai, P. Dilated common bile ducts mimicking choledochal cysts in ketamine abusers. Hong Kong Med J. 2009; 15(1), 53-56.
 [47]. Copeland, J., & Dillon, P. The health and psycho-social consequences of ketamine use. International Journal of Drug Policy. 2005; 16(2), 122-131.
[48]. Lian, K., Zhang, P., Niu, L., Bi, S., Liu, S., Jiang, L., & Kang, W. A novel derivatization approach for determination of ketamine in urine and plasma by gas chromatography–mass spectrometry. Journal of Chromatography A. 2012; 1264, 104-109.
[49]. Xiong, J., Chen, J., He, M., & Hu, B. Simultaneous quantification of amphetamines, caffeine and ketamine in urine by hollow fiber liquid phase microextraction combined with gas chromatography-flame ionization detector. Talanta. 2010; 82(3), 969-975.
 [50]. Kim, J. Y., Jung, K. S., Kim, M. K., Lee, J. I., & In, M. K. Simultaneous determination of psychotropic phenylalkylamine derivatives in human hair by gas chromatography/mass spectrometry. Rapid communications in mass spectrometry. 2007; 21(11), 1705-1720.
[51]. Bolze, S., & Boulieu, R. HPLC determination of ketamine, norketamine, and dehydronorketamine in plasma with a high-purity reversed-phase sorbent. Clinical chemistry. 1998; 44(3), 560-564.
[52]. Parkin, M. C., Turfus, S. C., Smith, N. W., Halket, J. M., Braithwaite, R. A., Elliott, S. P., . . . Kicman, A. T. Detection of ketamine and its metabolites in urine by ultra high pressure liquid chromatography–tandem mass spectrometry. Journal of Chromatography B. 2008; 876(1), 137-142.
 [53]. Moreno, I., Da Fonseca, B., Magalhães, A., Geraldes, V., Queiroz, J., Barroso, M., Gallardo, E. Rapid determination of piperazine-type stimulants in human urine by microextraction in packed sorbent after method optimization using a multivariate approach. Journal of Chromatography A. 2012; 1222, 116-120.
[54]. Svensson, J.-O., & Gustafsson, L. L. Determination of ketamine and norketamine enantiomers in plasma by solid-phase extraction and high-performance liquid chromatography. Journal of Chromatography B: Biomedical Sciences and Applications. 1996; 678(2), 373-376.
 [55]. Seay, S. S., Aucoin, D. P., & Tyczkowska, K. L. Rapid high-performance liquid chromatographic method for the determination of ketamine and its metabolite dehydronorketamine in equine serum. Journal of Chromatography B: Biomedical Sciences and Applications. 1993; 620(2), 281-287.
 
 
 
 
 
 
 
 
 
 
 
 
 
دوره 26، شماره 2
خرداد و تیر 1398
صفحه 263-271
  • تاریخ دریافت: 30 اردیبهشت 1397
  • تاریخ بازنگری: 02 مرداد 1397
  • تاریخ پذیرش: 25 تیر 1398
  • تاریخ اولین انتشار: 25 تیر 1398